An adamantane-conjugated Semax analog with enhanced lipophilicity and blood-brain barrier penetration.
Adamax is a modified form of Semax conjugated with an adamantane group — a bulky, lipophilic cage-like hydrocarbon structure also found in pharmaceutical drugs like amantadine and memantine (both used in neurology). The adamantane conjugation increases the peptide's lipophilicity, theoretically enhancing its ability to cross the blood-brain barrier and penetrate neural tissue.
Adamantane compounds have independent neuroprotective properties — amantadine is used for Parkinson's disease and memantine for Alzheimer's. The combination of Semax's BDNF-enhancing and neuroprotective effects with adamantane's own neurological properties may provide additive or synergistic cognitive benefits.
Adamax is the least studied of the Semax variants. It is primarily available through research chemical suppliers and specialized compounding sources. Clinical data specific to this compound is essentially absent.
The adamantane modification is pharmacologically sound — increasing lipophilicity improves CNS penetration for peptides. Adamantane-modified compounds have established precedent in neuropharmacology (amantadine, memantine).
No formal clinical studies exist for Adamax specifically. Evidence is extrapolated from parent Semax data and adamantane pharmacology principles. User reports suggest enhanced cognitive effects but these are anecdotal.
Very limited safety data. Theoretical profile combines Semax safety with adamantane compound characteristics. Adamantane compounds can cause CNS side effects (insomnia, agitation, hallucinations at high doses). Highly experimental — not recommended without medical supervision.
NOT FDA-approved. Research chemical. Very limited data.